Episodes
-
302: Vertex's big deal, biotech's red numbers, & an industry history lesson
Not summarized yet
-
301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
Not summarized yet
-
300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
Not summarized yet
-
299: Live! From the STAT Breakthrough Summit East
Not summarized yet
-
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
Not summarized yet
-
297: VC turmoil, GLP-1 competition, & the war on recovery
Not summarized yet
-
296: Legal insider trading, booming biotech stocks, & the next GLP-1
Not summarized yet
-
295: Humira’s legacy, CEO symbolism, and genomic surgery
Not summarized yet
-
294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking
Not summarized yet
-
293: AI in medicine, detangling hype, and Icelandic DNA
Not summarized yet
-
292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon
Not summarized yet
-
291: The plight of the VC, Gilead's latest setback, & more M&A
Not summarized yet
-
290: Biotech layoffs, slumping stocks, and a 2024 preview
Not summarized yet
-
289: Live! From #JPM24
Not summarized yet
-
287: 2023 in review, CEO report cards, and a look at the year ahead
Not summarized yet
-
286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future
Not summarized yet
-
285: CRISPR history, biotech struggles, & a big week for deals
Not summarized yet
-
284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
Not summarized yet
-
283: A CRISPR milestone, algorithms amok, & biotech mixology
Not summarized yet
-
From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?
Not summarized yet
Follow this show on AudioBrevity and new episodes get summarized for you. Create a free account